http://www.reportlinker.com/ci02257/Pharmaceutical.html/coverage/Europe:Germany/mode/premium Wed, 22 May 2013 05:50:24 +0000 helpdesk@reportlinker.com Copyright 2013, Reportlinker Zend_Feed en-us http://blogs.law.harvard.edu/tech/rss http://www.reportlinker.com/p01171143/Evista-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171143/Evista-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171156/Aprela-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171156/Aprela-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aprela (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171157/Romosozumab-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171157/Romosozumab-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Romosozumab (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Romosozumab (Osteoporosis) - Forecast and Market Analysis ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171160/PTH-1-31-NH2-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171160/PTH-1-31-NH2-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171159/BA-058-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171159/BA-058-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171150/Protelos-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171150/Protelos-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171158/Odanacatib-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171158/Odanacatib-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171147/Forteo-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171147/Forteo-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171145/Reclast-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171145/Reclast-Osteoporosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01158413/PharmaPoint-Osteoporosis-Germany-Drug-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01158413/PharmaPoint-Osteoporosis-Germany-Drug-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - Germany Drug Forecast and Market Analysis ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01171142/PharmaPoint-Multiple-Sclerosis-Germany-Drug-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171142/PharmaPoint-Multiple-Sclerosis-Germany-Drug-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p080429/World-Herbal-Supplements-and-Remedies-Market.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p080429/World-Herbal-Supplements-and-Remedies-Market.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This report analyzes the worldwide markets for Herbal Supplements and Remedies in US$ Million by the following Product Segments: Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera, ...]]> Thu, 28 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01181925/Vaccines-Top-10-Global-Markets-Package.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01181925/Vaccines-Top-10-Global-Markets-Package.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...]]> Sun, 19 May 2013 22:00:00 +0000 http://www.reportlinker.com/p01158474/MediPoint-Predictive-Breast-Cancer-Gene-Testing-EU-Analysis-and-Market-Forecasts.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01158474/MediPoint-Predictive-Breast-Cancer-Gene-Testing-EU-Analysis-and-Market-Forecasts.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts Summary Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence ...]]> Wed, 27 Feb 2013 23:00:00 +0000 http://www.reportlinker.com/p01158446/EpiCast-Report-Dry-Eye-Syndrome-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01158446/EpiCast-Report-Dry-Eye-Syndrome-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022 Summary Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01158447/EpiCast-Report-Psoriasis-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01158447/EpiCast-Report-Psoriasis-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium EpiCast Report: Psoriasis - Epidemiology Forecast to 2022 Summary Psoriasis is an immune-mediated chronic disorder of the skin characterized by redness and irritation. It affects people of both sexes ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01163172/EpiCast-Report-Chronic-Myeloid-Leukemia-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01163172/EpiCast-Report-Chronic-Myeloid-Leukemia-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 Summary Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth ...]]> Thu, 11 Apr 2013 22:00:00 +0000 http://www.reportlinker.com/p01163173/EpiCast-Report-Cystic-Fibrosis-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01163173/EpiCast-Report-Cystic-Fibrosis-Epidemiology-Forecast-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022 Summary Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-New-product-entries-in-both-niche-and-broader-Parkinson-s-disease-treatment-will-boost-market-despite-patent-cliff.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01154050/Neurodegenerative-Diseases-Market-to-New-product-entries-in-both-niche-and-broader-Parkinson-s-disease-treatment-will-boost-market-despite-patent-cliff.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff Summary GBI Research, the leading business ...]]> Tue, 19 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01182957/Ocrelizumab-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01182957/Ocrelizumab-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ocrelizumab (Multiple Sclerosis) - Forecast and Market ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01182958/Daclizumab-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01182958/Daclizumab-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Daclizumab (Multiple Sclerosis) - Forecast and Market ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01182953/Aubagio-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01182953/Aubagio-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Aubagio (Multiple Sclerosis) - Forecast and Market Analysis ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01182960/Siponimod-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01182960/Siponimod-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Siponimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Siponimod (Multiple Sclerosis) - Forecast and Market ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01182959/Masitinib-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01182959/Masitinib-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Masitinib (Multiple Sclerosis) - Forecast and Market ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171162/Gilenya-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171162/Gilenya-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Gilenya (Multiple Sclerosis) - Forecast and Market Analysis ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171167/Copaxone-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171167/Copaxone-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Copaxone (Multiple Sclerosis) - Forecast and Market ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171164/Tysabri-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171164/Tysabri-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Tysabri (Multiple Sclerosis) - Forecast and Market Analysis ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171163/Rebif-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171163/Rebif-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Rebif (Multiple Sclerosis) - Forecast and Market Analysis ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171166/Avonex-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171166/Avonex-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Avonex (Multiple Sclerosis) - Forecast and Market Analysis ...]]> Sat, 30 Mar 2013 23:00:00 +0000 http://www.reportlinker.com/p01171165/Betaseron-Betaferon-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium http://www.reportlinker.com/p01171165/Betaseron-Betaferon-Multiple-Sclerosis-Forecast-and-Market-Analysis-to.html?utm_source=distribution#utm_campaign=distribution_kidela#utm_medium=distribution_premium Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Betaseron/Betaferon (Multiple Sclerosis) ...]]> Sat, 30 Mar 2013 23:00:00 +0000